PHASE I/II STUDY OF SAFETY/TOLERANCE/PK/ANTIVIRIAL ACTIVITY OF DMPA IN HIV

DMPA 在 HIV 中的安全性/耐受性/药代动力学/抗病毒活性的 I/II 期研究

• 批准号: 6115465
• 负责人: STEVEN Grant DEEKS
• 金额: $ 3.1万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6115465
• 关键词: AIDS; AIDS therapy; HIV infections; aniline; antiviral agents; clinical research; drug screening /evaluation; human immunodeficiency virus 1; human subject; human therapy evaluation; nucleotide analog; outcomes research; pharmacokinetics; virus RNA

This is a phase I/II study evaluating the safety, pharmacokinetics and efficacy of PMPA in HIV-1 infected patients. PMPA is a novel nucleotide analog which has been shown to be very potent in animal models. PMPA will be infused over 30 minutes. Extensive pharmacokinetic, safety and viral RNA sampling will be done during 2 weeks of study and 4 weeks of follow- up.

这是一项I/II期研究，评估了安全性、药代动力学和 PMPA治疗HIV-1感染者的疗效观察PMPA是一种新的核苷酸 已被证明在动物模型中非常有效的类似物。PMPA将 输液超过30分钟。广泛的药物动力学、安全性和病毒学 RNA样本将在2周的研究和4周的随访中进行- 向上。